Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease

Scott E. Counts, Balmiki Ray, Elliott J. Mufson, Sylvia E. Perez, Bin He, Debomoy K. Lahiri

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Intravenous immunoglobulin (IVIG) has shown limited promise so far in human clinical studies on Alzheimer's disease (AD), yet overwhelmingly positive preclinical work in animals and human brain cultures support the notion that the therapy remains potentially efficacious. Here, we elaborate on IVIG neuropreservation by demonstrating that IVIG protects human primary neurons against oxidative stress in vitro and that IVIG preserves antioxidant defense mechanisms in vivo. Based on these results, we propose the following translational impact: If the dosage and treatment conditions are adequately optimized, then IVIG treatment could play a significant role in preventing and/or delaying the progression of neurodegenerative diseases, such as AD. We suggest that IVIG warrants further investigation to fully exploit its potential as an anti-oxidant, neuroprotective and synapto-protecting agent.

Original languageEnglish (US)
Pages (from-to)S80-S85
JournalJournal of Clinical Immunology
Volume34
Issue numberSUPPL. 1
DOIs
StatePublished - Jul 2014

Keywords

  • Alzheimer's disease
  • Human neurons
  • Immunoglobulin
  • Neuroprotection
  • Oxidative stress
  • Transgenic

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease'. Together they form a unique fingerprint.

  • Cite this